Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: A meta-Analysis

Molecules

Volumn 19, Issue 5, 2014, Pages 6282-6293

  Wang, Faliang ^a,c   Hou, Jinchao ^b   Jin, Wei ^a   Li, Jiaqiu ^a   Yue, Yongfang ^a   Jin, Hongchuan ^a   Wang, Xian ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarker; Breast cancer; Circulating miRNAs; MicroRNA 155

Indexed keywords

MICRORNA; MIRN155 MICRORNA, HUMAN; TUMOR MARKER;

BLOOD; BREAST TUMOR; CHINA; EARLY DIAGNOSIS; FEMALE; HUMAN; META ANALYSIS; PATHOLOGY;

BREAST NEOPLASMS; CHINA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901448602     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19056282     Document Type: Article

References (41)

1. Siegel R.; Naishadham D.; Jemal A. Cancer statistics, 2013. CA: Cancer J. Clin. 2013, 63, 11-30.
2. DeSantis C.; Ma J.; Bryan L.; Jemal A. Breast cancer statistics, 2013. CA: Cancer J. Clin. 2014, 64, 52-62.
3. Siegel R.; Ward E.; Brawley O.; Jemal A. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J. Clin. 2011, 61, 212-236.
4. Flynt A.S.; Lai E.C. Biological principles of microRNA-mediated regulation: Shared themes amid diversity. Nat. Rev. Genet. 2008, 9, 831-842.
5. Carthew R.W.; Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642-655.
6. Wu L.; Fan J.; Belasco J.G. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. USA 2006, 103, 4034-4039.
7. Lewis B.P.; Burge C.B.; Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15-20.
8. Calin G.A.; Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
9. Chen X.; Ba Y.; Ma L.; Cai X.; Yin Y.; Wang K.; Guo J.; Zhang Y.; Chen J.; Guo X. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006.
10. Iguchi H.; Kosaka N.; Ochiya T. Secretory microRNAs as a versatile communication tool. Commun. Integr. Biol. 2010, 3, 478-481.
11. Mitchell P.S.; Parkin R.K.; Kroh E.M.; Fritz B.R.; Wyman S.K.; Pogosova-Agadjanyan E.L.; Peterson A.; Noteboom J.; O'Briant K.C.; Allen A. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
12. Heneghan H.M.; Miller N.; Lowery A.J.; Sweeney K.J.; Newell J.; Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251, 499-505.
13. Kosaka N.; Iguchi H.; Ochiya T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101, 2087-2092.
14. Jiang S.; Zhang H.-W.; Lu M.-H.; He X.-H.; Li Y.; Gu H.; Liu M.-F.; Wang E.-D. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70, 3119-3127.
15. Iorio M.V.; Ferracin M.; Liu C.-G.; Veronese A.; Spizzo R.; Sabbioni S.; Magri E.; Pedriali M.; Fabbri M.; Campiglio M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070.
16. Lu Z.; Ye Y.; Jiao D.; Qiao J.; Cui S.; Liu Z. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol. Lett. 2012, 4, 1027-1032.
17. Sun Y.; Wang M.; Lin G.; Sun S.; Li X.; Qi J.; Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012, 7, e47003.
18. Mar-Aguilar F.; Mendoza-Ramirez J.A.; Malagon-Santiago I.; Espino-Silva P.K.; Santuario-Facio S.K.; Ruiz-Flores P.; Rodriguez-Padilla C.; Resendez-Perez D. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis. Markers 2013, 34, 163-169.
19. Zhu W.; Qin W.; Atasoy U.; Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2009, doi:10.1186/1756-0500-2-89.
20. Zhao S.Y.; Wu Q.; Gao F.; Zhang C.B.; Yang X.W. Serum microRNA-155 as a potential biomarker for breast cancer screening. Chin. Sci. Bull. 2012, 57, 3466-3468.
21. Zamora J.; Abraira V.; Muriel A.; Khan K.; Coomarasamy A. Meta-DiSc: A software for meta-Analysis of test accuracy data. BMC Med. Res. Methodol. 2006, 6, 31.
22. Esquela-Kerscher A.; Slack F.J. Oncomirs-MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
23. Le Quesne J.; Caldas C. Micro-RNAs and breast cancer. Mol. Oncol. 2010, 4, 230-241.
24. Yu Z.; Baserga R.; Chen L.; Wang C.; Lisanti M.P.; Pestell R.G. microRNA, cell cycle, and human breast cancer. Breast Cancer Res. Treat. 2010, 176, 1058-1064.
25. Blenkiron C.; Goldstein L.D.; Thorne N.P.; Spiteri I.; Chin S.-F.; Dunning M.J.; Barbosa-Morais N.L.; Teschendorff A.E.; Green A.R.; Ellis I.O. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8, R214.
26. Kastl L.; Brown I.; Schofield A. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res. Treat. 2012, 131, 445-454.
27. Zhu Y.; Yu F.; Jiao Y.; Feng J.; Tang W.; Yao H.; Gong C.; Chen J.; Su F.; Zhang Y. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res. 2011, 17, 7105-7115.
28. Calin G.A.; Sevignani C.; Dumitru C.D.; Hyslop T.; Noch E.; Yendamuri S.; Shimizu M.; Rattan S.; Bullrich F.; Negrini M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
29. Huang Z.; Huang D.; Ni S.; Peng Z.; Sheng W.; Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127, 118-126.
30. Roth C.; Rack B.; Muller V.; Janni W.; Pantel K.; Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12, R90.
31. Glas A.S.; Lijmer J.G.; Prins M.H.; Bonsel G.J.; Bossuyt P.M. The diagnostic odds ratio: A single indicator of test performance. J. Clin. Epidemiol. 2003, 56, 1129-1135.
32. Jones C.M.; Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann. Thorac. Surg. 2005, 79, 16-20.
33. Walter S. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat. Med. 2002, 21, 1237-1256.
34. Althuis M.D.; Dozier J.M.; Anderson W.F.; Devesa S.S.; Brinton L.A. Global trends in breast cancer incidence and mortality 1973-1997. Int. J. Epidemiol. 2005, 34, 405-412.
35. Faraoni I.; Antonetti F.R.; Cardone J.; Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochim. Biophys. Acta 2009, 1792, 497-505.
36. Whiting P.; Rutjes A.W.; Reitsma J.B.; Bossuyt P.M.; Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 2003, 3, 25.
37. Devillé W.L.; Buntinx F.; Bouter L.M.; Montori V.M.; de Vet H.C.; van der Windt D.A.; Bezemer P.D. Conducting systematic reviews of diagnostic studies: Didactic guidelines. BMC Med. Res. Methodol. 2002, 2, 9.
38. Mitchell A.J.; Vaze A.; Rao S. Clinical diagnosis of depression in primary care: A meta-Analysis. Lancet 2009, 374, 609-619.
39. Vamvakas E.C. Meta-Analyses of studies of the diagnostic accuracy of laboratory tests: A review of the concepts and methods. Arch. Pathol. Lab. Med. 1998, 122, 675-686.
40. Higgins J.P.; Thompson S.G.; Deeks J.J.; Altman D.G. Measuring inconsistency in meta-Analyses. BMJ 2003, 327, 557-560.
41. Dinnes J.; Deeks J.; Kirby J.; Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol. Assess. 2005, 9, 1-113.